Vanda Pharmaceuticals to be Acquired for $465M
Ticker: VNDA · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, deal
TL;DR
Vanda Pharmaceuticals is being bought out by FutureGen Acquisition Corp. for $465M, deal expected to close H2 2024.
AI Summary
Vanda Pharmaceuticals Inc. announced on March 6, 2024, that it has entered into a definitive agreement to be acquired by FutureGen Acquisition Corp. for approximately $465 million. The transaction is expected to close in the second half of 2024, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition by FutureGen Acquisition Corp. signifies a major financial event for Vanda Pharmaceuticals, potentially impacting its stock value and future operations.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty regarding the completion of the deal.
Key Numbers
- $465 million — Acquisition Value (Total amount Vanda Pharmaceuticals will be acquired for.)
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- FutureGen Acquisition Corp. (company) — Acquiring entity
- $465 million (dollar_amount) — Acquisition price
- March 6, 2024 (date) — Date of agreement
- second half of 2024 (date) — Expected closing period
FAQ
What is the exact date the definitive agreement was entered into?
The definitive agreement was entered into on March 6, 2024.
Who is acquiring Vanda Pharmaceuticals?
FutureGen Acquisition Corp. is acquiring Vanda Pharmaceuticals.
What is the total value of the acquisition?
The acquisition is valued at approximately $465 million.
When is the acquisition expected to close?
The transaction is expected to close in the second half of 2024.
What are the conditions for the acquisition to be completed?
The acquisition is subject to customary closing conditions and regulatory approvals.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-07 16:31:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d764198d8k.htm (8-K) — 24KB
- d764198dex991.htm (EX-99.1) — 4KB
- g764198g0307074350948.jpg (GRAPHIC) — 4KB
- 0001193125-24-062241.txt ( ) — 155KB
- vnda-20240306.xsd (EX-101.SCH) — 3KB
- vnda-20240306_lab.xml (EX-101.LAB) — 18KB
- vnda-20240306_pre.xml (EX-101.PRE) — 11KB
- d764198d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated March 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 7, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary